Immix Biopharma, Inc. develops clinical-stage cell therapies focused on relapsed/refractory AL Amyloidosis, led by NXC-201, a sterically optimized BCMA-targeted CAR-T therapy. Company news commonly covers NXC-201 clinical data from the NEXICART-2 study, FDA designations such as Breakthrough Therapy, RMAT and orphan-drug status, and regulatory-development planning.
Updates also include equity financings, pre-funded warrants, private placements, investor-conference participation, and commercial and medical leadership additions tied to the company’s rare-disease oncology and hematology strategy.
Immix Biopharma (IMMX) closed its previously announced $125 million underwritten offering of common stock, adding funding for its development plans.
The company sold 11,363,637 shares at $11.00 per share and received approximately $117.1 million in net proceeds after underwriting discounts, commissions and other offering expenses. Immix intends to use the proceeds to fund NXC-201 development, working capital and general corporate purposes. U.S. biotechnology institutional investors and mutual funds participated, and J.P. Morgan served as sole book-running manager.
Immix Biopharma (IMMX) priced an underwritten common-stock offering expected to generate $125 million in gross proceeds.
The offering covers 11,363,637 shares at $11.00 each. It is expected to close on or about September 30, 2026, subject to customary closing conditions. Gross proceeds are before underwriting discounts, commissions and offering expenses payable by Immix. The company intends to use net proceeds for NXC-201 development, working capital and general corporate purposes. New and existing institutional investors participated.
Immix Biopharma (IMMX) reported an 89% complete response rate across all 45 patients in its interim NEXICART-2 trial update.
An independent review committee found complete responses in 40 of 45 patients treated with NXC-201 in the Phase 2 study of relapsed or refractory AL amyloidosis. Among 25 newly reported patients, 21 reached complete response and the remaining four were negative for minimum residual disease (MRD), a bone-marrow measure. Those four have not yet reached complete response; Immix says their MRD-negative results could lift the eventual rate to as much as 98% (44 of 45). No relapses have been observed among patients reaching complete response or MRD-negativity, and no neurotoxicity or enterocolitis has been observed to date.
Immix plans the final NEXICART-2 readout and a biologics license application (BLA) submission for mid-2027.
Immix Biopharma (Nasdaq: IMMX) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY, on September 14-16, 2026, hosting institutional investor one-on-one meetings. Interested investors are directed to contact their Morgan Stanley representative to request meetings.
According to Immix Biopharma, a replay link of its participation will be posted on the company’s website under the Investors > Presentation & Events section when available. The company highlights its lead AL Amyloidosis CAR-T candidate NXC-201, which is being evaluated in the U.S. multi-center NEXICART-2 study and has received FDA Breakthrough Therapy, RMAT, and Orphan Drug designations, as well as EMA Orphan Drug designation.
Immix Biopharma (IMMX) closed a $150 million underwritten registered offering of common stock, selling 16,778,524 shares at $8.94 per share.
According to Immix Biopharma, net proceeds were about $140.65 million. The financing included leading U.S. biotechnology institutional investors and mutual funds.
Immix Biopharma (NASDAQ: IMMX) priced an underwritten registered offering of 16,778,524 common shares at $8.94 per share, for expected gross proceeds of $150 million.
Net proceeds will fund NXC-201 development, working capital and general corporate purposes, supporting operations into mid‑2028, subject to closing around May 22, 2026.
Immix Biopharma (IMMX) reported an interim update from its relapsed/refractory AL Amyloidosis trial NEXICART-2.
The NXC-201 therapy shows a 95% complete response (CR) rate (19/20 patients), with all CRs achieved within 1 year, no relapses among CR patients to date, and all later patients with available data MRD-negative at one month. A multi-center randomized Phase 3 in newly diagnosed patients is planned, with the next NEXICART-2 update expected in late September 2026 and 1-year follow-up data targeted by end of March 2027.
Immix Biopharma (NASDAQ:IMMX) will participate in the Jefferies Global Healthcare Conference June 2-4, 2026 in New York.
The company said it will host one-on-one institutional investor meetings and that a replay link will be posted to its Presentation & Events page on the investor website when available.
Immix Biopharma (NASDAQ:IMMX) announced completion of enrollment in its BLA‑enabling NEXICART‑2 trial for relapsed/refractory AL amyloidosis, meeting prior guidance. Topline NEXICART‑2 results are expected in Q3 2026, followed by a planned BLA submission and intended commercial launch.
The company also appointed Dr. Richard Graydon as Chief Medical Officer; Dr. Graydon has led new and supplemental drug and biologics applications at Merck and Johnson & Johnson for multiple approved therapies.
Immix Biopharma (NASDAQ:IMMX) will present and host investor meetings at two institutional conferences in Miami Beach in March 2026. Management will attend the Leerink Partners 2026 Global Healthcare Conference March 8–11 and Citizens Life Sciences Conference March 10–11, 2026.
One-on-one meetings are available via conference representatives; replay links will be posted on the company Presentation & Events page when available.